Connection

Mark Rubinstein to Antineoplastic Combined Chemotherapy Protocols

Back to Details
This is a "connection" page, showing publications Mark Rubinstein has written about Antineoplastic Combined Chemotherapy Protocols.
Mark Rubinstein
Connection Strength
0.479
Antineoplastic Combined Chemotherapy Protocols
  1. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018 05; 19(5):694-704.
    View in: PubMed
    Score: 0.479
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.